Phenytoin (All indications) updated on 04-22-2025

ASD (Autism spectrum disorder): Diagnosis

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19381
R82286
Straub (Controls exposed to LTG) (Phenytoin) (Epilepsy), 2026 Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.90 [0.47;1.71] C
excluded (control group)
13/1,390   34/3,273 47 1,390
ref
S19370
R82142
Straub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes 0.54 [0.29;0.98] 13/1,390   106/8,887 119 1,390
ref
S17390
R72904
Madley-Dowd_SE (Phenytoin) (Controls exposed to LTG) (Mixed indications), 2024 Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes 1.18 [0.62;2.24]
excluded (control group)
10/194   134/5,035 144 194
ref
S17391
R72910
Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.97 [0.52;1.82] 10/194   68,788/2,651,210 68,798 194
ref
S17392
R72916
Madley-Dowd_SE (Phenytoin) (Controls unexposed, sibling) (Mixed indications), 2024 Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective sibling excluded Adjustment: Yes 5.34 [0.70;40.88]
excluded (control group)
-/-   -/- - -
ref
S17283
R72333
Madley-Dowd_UK (Phenytoin) (Controls exposed to LTG) (Mixed indications), 2024 Autism - ICD10 codes - Median follow up 10.75 (7.82-13.62) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.09 [0.15;7.66]
excluded (control group)
-/46   20/939 - 46
ref
S17268
R72288
Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Autism - ICD10 codes - Median follow up 10.75 (7.82-13.62) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.19 [0.18;8.05] -/46   7,657/514,066 - 46
ref
S17276
R72312
Madley-Dowd_UK (Phenytoin) (Controls unexposed, sibling) (Mixed indications), 2024 Autism - ICD10 codes - Median follow up 10.75 (7.82-13.62) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) sibling excluded Adjustment: Yes 15.33 [4.45;52.85]
excluded (control group)
-/-   -/- - -
ref
S9256
R32098
Bromley (Phenytoin) (Controls exposed to Lamotrigine, sick), 2008 Autism spectrum disorder (a majority aged 6 and above) early pregnancy prospective cohort exposed to other treatment, sick excluded Adjustment: No 5.38 [0.30;95.06] C
excluded (control group)
1/9   1/44 2 9
ref
S9257
R32099
Bromley (Phenytoin) (Controls unexposed, disease free), 2008 Autism spectrum disorder (a majority aged 6 and above) early pregnancy prospective cohort unexposed, disease free excluded Adjustment: No 13.88 [1.30;148.33] C
excluded (control group)
1/9   3/336 4 9
ref
S9258
R32100
Bromley (Phenytoin) (Controls unexposed, sick), 2008 Autism spectrum disorder (a majority aged 6 and above) early pregnancy prospective cohort unexposed, sick Adjustment: No 18.60 [0.69;500.42] C 1/9   0/47 1 9
ref
Total 4 studies 0.88 [0.43;1.80] 68,918 1,639
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Straub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026Straub, 2026 1 0.54[0.29; 0.98]1191,39042%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_SE, 2024 2 0.97[0.52; 1.82]68,79819442%ROB confusion: seriousROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK, 2024 3 1.19[0.18; 8.05]-4611%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Bromley (Phenytoin) (Controls unexposed, sick), 2008Bromley, 2008 4 18.60[0.69; 500.42]194%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 47% 0.88[0.43; 1.80]68,9181,6390.250.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick) (Phenytoin) (Epilepsy; 2: Phenytoin) (Controls unexposed, general pop) (Mixed indications; 3: Phenytoin) (Controls unexposed, general pop) (Mixed indications; 4: Phenytoin) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.88[0.43; 1.80]68,9181,63947%NAStraub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Bromley (Phenytoin) (Controls unexposed, sick), 2008 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.99[0.55; 1.79]68,7982400%NAMadley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 2 unexposed, sickunexposed, sick 2.16[0.07; 63.69]1201,39977%NAStraub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Bromley (Phenytoin) (Controls unexposed, sick), 2008 2 Tags Adjustment   - No  - No 18.60[0.69; 500.42]19 -NABromley (Phenytoin) (Controls unexposed, sick), 2008 1   - Yes  - Yes 0.74[0.48; 1.13]68,9171,6300%NAStraub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 3 All studiesAll studies 0.88[0.43; 1.80]68,9181,63947%NAStraub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Bromley (Phenytoin) (Controls unexposed, sick), 2008 40.250.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.03.82.0160.000Straub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024Bromley (Phenytoin) (Controls unexposed, sick), 2008

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9256, 9257, 17390, 17392, 17283, 17276, 19381

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.79[0.46; 6.93]76,45024956%NAMadley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 Bromley (Phenytoin) (Controls unexposed, disease free), 2008 3 unexposed, sick controlsunexposed, sick controls 2.16[0.07; 63.69]1201,39977%NAStraub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 Bromley (Phenytoin) (Controls unexposed, sick), 2008 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.07[0.69; 1.66]2041,6390%NAStraub (Controls exposed to LTG) (Phenytoin) (Epilepsy), 2026 Madley-Dowd_SE (Phenytoin) (Controls exposed to LTG) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls exposed to LTG) (Mixed indications), 2024 Bromley (Phenytoin) (Controls exposed to Lamotrigine, sick), 2008 4 siblingssiblings Out of scale11.53[4.01; 33.18]--0%NAMadley-Dowd_SE (Phenytoin) (Controls unexposed, sibling) (Mixed indications), 2024 Madley-Dowd_UK (Phenytoin) (Controls unexposed, sibling) (Mixed indications), 2024 20.510.01.0